MeSH Review:
Myasthenia Gravis, Autoimmune, Experimental
- Antibodies against nicotinic acetylcholine receptor and skeletal muscle in human and experimental myasthenia gravis. Aarli, J.A., Mattsson, C., Heilbronn, E. Scand. J. Immunol. (1975)
- Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. Im, S.H., Barchan, D., Maiti, P.K., Raveh, L., Souroujon, M.C., Fuchs, S. FASEB J. (2001)
- Dimethyl sulphoxide reduces anti-receptor antibody titres in experimental myasthenia gravis. Pestronk, A., Drachman, D.B. Nature (1980)
- Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. Im, S.H., Barchan, D., Fuchs, S., Souroujon, M.C. J. Clin. Invest. (1999)
- Muscle responds to an antibody reactive with the acetylcholine receptor by up-regulating monocyte chemoattractant protein 1: a chemokine with the potential to influence the severity and course of experimental myasthenia gravis. Reyes-Reyna, S., Stegall, T., Krolick, K.A. J. Immunol. (2002)
- Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. Karachunski, P.I., Ostlie, N.S., Monfardini, C., Conti-Fine, B.M. J. Immunol. (2000)
- IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis. Deng, C., Goluszko, E., Baron, S., Wu, B., Christadoss, P. J. Immunol. (1996)
- Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. Biesecker, G., Gomez, C.M. J. Immunol. (1989)
- Ampicillin may aggravate clinical and experimental myasthenia gravis. Argov, Z., Brenner, T., Abramsky, O. Arch. Neurol. (1986)
- Treatment of experimental myasthenia with autologous idiotypes linked to muramyl dipeptide. Valderrama, R., Eggers, A.E., Moomjy, M., Kao, P.N., Michl, J. Clin. Exp. Immunol. (1988)
- Dimethyl sulfoxide does not suppress the clinical manifestations of collagen arthritis. Trentham, D.E., Rowland, D. J. Rheumatol. (1983)
- Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Pestronk, A., Drachman, D.B., Adams, R.N. Muscle Nerve (1982)
- Myocytes respond in vivo to an antibody reactive with the acetylcholine receptor by upregulating interleukin-15: an interferon-gamma activator with the potential to influence the severity and course of experimental myasthenia gravis. Stegall, T., Krolick, K.A. J. Neuroimmunol. (2001)
- An immunodominant site of acetylcholine receptor in experimental myasthenia mapped with T lymphocyte clones and synthetic peptides. Pachner, A.R., Kantor, F.S., Mulac-Jericevic, B., Atassi, M.Z. Immunol. Lett. (1989)
- Myocytes respond to both interleukin-4 and interferon-gamma: cytokine responsiveness with the potential to influence the severity and course of experimental myasthenia gravis. Stegall, T., Krolick, K.A. Clin. Immunol. (2000)
- Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. Karachunski, P.I., Ostlie, N.S., Okita, D.K., Conti-Fine, B.M. J. Neuroimmunol. (1999)
- Cathepsin S is not crucial to TSHR processing and presentation in a murine model of Graves' disease. Kala, M., Chen, C.R., McLachlan, S.M., Rapoport, B., Aliesky, H., Chapman, H.A. Immunology (2005)
- Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Vassilev, T., Yamamoto, M., Aissaoui, A., Bonnin, E., Berrih-Aknin, S., Kazatchkine, M.D., Kaveri, S.V. Eur. J. Immunol. (1999)
- Experimental myasthenia gravis induced in mice by passive transfer of human myasthenic immunoglobulin. Evidence for an ameliorating effect by alpha-fetoprotein. Buschman, E., van Oers, N., Katz, M., Murgita, R.A. J. Neuroimmunol. (1987)
- Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Okumura, S., McIntosh, K., Drachman, D.B. Ann. Neurol. (1994)